BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 3, 2003
View Archived Issues
CV Therapeutics Stock Drops On Ranexa Approvable Letter
CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today)
Read More
Fast Action Urged To Rescue Reef Cone Snails From Global Warming, To Garner Rich Trove Of Medicines
Read More
With Venter On Board, Ionian Has Biothreat Detection Focus
Read More
Other News To Note
Read More